VALLARIS™ measures the grant-date fair value of share options, restricted share units and performance shares, so the expense is right in the accounts and the plan does what it was designed to do.
Share-based payment valuation measures the fair value of equity awards given to employees and others, such as share options, restricted shares and performance shares, at the grant date. The fair value is expensed over the vesting period under IFRS 2 (SFRS(I) 2 in Singapore). Black-Scholes, binomial lattice and Monte Carlo models are used, chosen by the plan’s vesting and market conditions.
You want the expense modelled before the plan is approved, so the design and the accounts agree.
Each grant needs a fair value at its grant date for the year-end accounts.
A modification, a repricing or a cash settlement needs the incremental value measured.
A share plan is a promise to your people, and the accounts have to show what it costs. I value each award against its own conditions, so the number stands up to the auditor.
Siong Yoong
About VALLARIS™ →
CVA, Institute of Valuers and Appraisers, Singapore (IVAS).
Member since 2018 of the IVAS Standards & Technical Working Group, which writes Singapore’s business valuation standards.
Member, Memberships & Standards Recognition Committee, IVSC, the body that publishes the IVS.
Six questions. Your score and focus areas appear as you answer. No email needed.
0 of 6 answered.
Thirty minutes, confidential, and no fee for the first conversation.
IFRS 2 Share-based Payment requires a company to recognise an expense for shares and options granted to employees and others, measured at fair value. In Singapore it applies as SFRS(I) 2.
Equity-settled awards are valued at the grant date and not remeasured. Cash-settled awards are remeasured at each reporting date until they are settled.
Black-Scholes suits simple options with no market conditions. A binomial lattice handles early exercise. Monte Carlo simulation is needed for market conditions such as total shareholder return targets.
Usually from the historical volatility of comparable listed companies, adjusted for differences in size and leverage, because a private company has no traded share price.
If a modification increases the fair value of the award, the incremental fair value at the modification date is expensed over the remaining vesting period, in addition to the original charge.
Financial instrument valuation measures the fair value of instruments that have no quoted price, such as convertible notes, preference shares, warrants, earn-outs and intercompany loans.
A business valuation sets what a company is worth, on a stated basis of value and at a stated date.
Portfolio company valuation sets the fair value of a fund’s unlisted investments at each reporting date, as required by IFRS 13 and set out in the IPEV Valuation Guidelines.